Insulet Co. (NASDAQ:PODD) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have received a consensus rating of “Moderate Buy” from the sixteen analysts that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $272.81.

PODD has been the topic of a number of recent analyst reports. Morgan Stanley raised their price target on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. BTIG Research raised their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price for the company. Piper Sandler raised their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Finally, Canaccord Genuity Group upped their price objective on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th.

Insider Activity at Insulet

In related news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.47% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently modified their holdings of PODD. QRG Capital Management Inc. bought a new position in shares of Insulet during the third quarter worth $297,000. Fisher Asset Management LLC boosted its holdings in shares of Insulet by 0.9% during the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after purchasing an additional 3,113 shares during the last quarter. Orion Portfolio Solutions LLC grew its position in shares of Insulet by 86.2% during the third quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock valued at $1,822,000 after purchasing an additional 3,623 shares in the last quarter. Nomura Asset Management Co. Ltd. increased its holdings in shares of Insulet by 5.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock worth $35,708,000 after purchasing an additional 8,301 shares during the last quarter. Finally, Stifel Financial Corp lifted its position in shares of Insulet by 2.8% in the third quarter. Stifel Financial Corp now owns 10,527 shares of the medical instruments supplier’s stock worth $2,450,000 after buying an additional 290 shares in the last quarter.

Insulet Trading Up 0.5 %

Shares of NASDAQ:PODD opened at $271.83 on Monday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet has a 1 year low of $160.19 and a 1 year high of $279.77. The company has a market cap of $19.07 billion, a P/E ratio of 46.55, a PEG ratio of 4.12 and a beta of 1.22. The stock’s fifty day moving average price is $263.96 and its 200-day moving average price is $230.50.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.